Octreotide Inhibits Choroidal Neovascularization in Rats
Octreotide Inhibits Choroidal Neovascularization in Rats
复制标题
DOI：
10.1159/000219683
复制
发表时间：
2009-01-01
影响因子：
2.1
通讯作者：
Wei, Fengcai
中科院分区：
文献类型：
--
作者：
Qu, Yi;Zhang, Shuihua;Wei, Fengcai
目的：奥曲肽在早产儿视网膜病变动物模型和增殖性糖尿病视网膜病变的临床病例中显示出抗血管生成活性。在本研究中，我们测试了使用奥曲肽抑制大鼠实验性脉络膜新生血管(CNV)的适用性。方法：成年大鼠15只，其中3只为非激光治疗对照组。其余12只大鼠用激光光凝诱导右眼CNV。12只大鼠随机分为两组，每组6只，分别于第一次注射后即刻和第3天球后注射奥曲肽(50 mU g/kg)或磷酸盐缓冲液(PBS)0.15 ml。术后14天行荧光素血管造影和视网膜色素上皮(RPE)-脉络膜平台物定量分析，评价CNV病变的变化。用实时定量逆转录-聚合酶链式反应(qRT-PCR)比较奥曲肽、PBS和非激光治疗大鼠(n=3)视网膜色素上皮-脉络膜复合体中血管内皮生长因子(VEGF)和胰岛素样生长因子(IGF)-1mRNA水平的变化。结果：奥曲肽治疗显著抑制荧光素渗漏和新生血管的程度，在诱导的CNV大鼠的脉络膜组织中观察到。经奥曲肽治疗后，血管内皮细胞生长因子和胰岛素样生长因子-1mRNA水平降低。结论：球后应用奥曲肽可能是治疗CNV的一种有效的新策略。版权所有(C)2009年S.Karger AG，巴塞尔
Aims: Octreotide exhibits anti-angiogenic activity in animal models of retinopathy of prematurity and in clinical cases of proliferative diabetic retinopathy. In this study, we tested the applicability of using octreotide for inhibiting experimental choroidal neovascularization (CNV) in rats. Methods: Of 15 adult rats used, 3 served as non-laser-treated controls. CNV was induced in the right eye of the remaining 12 rats by laser photocoagulation. These 12 rats were divided into two groups (n = 6 each) which were retrobulbarly injected with octreotide ( 50 mu g/kg) or phosphate-buffered saline (PBS) (0.15 ml) immediately and on day 3 after the first injection. Fluorescein angiography and quantitative analysis of the retinal pigment epithelium (RPE)-choroidal flat mounts were performed 14 days after the operation to evaluate the changes in the CNV lesions. Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) was used to compare the changes shown by the octreotide-, PBS-, and non-laser-treated rats (n = 3 each) with regard to mRNA levels of the vascular endothelial growth factor (VEGF) and insulin-like growth factor (IGF)-1 in the RPE-choroidal complex. Results: Octreotide treatment significantly inhibited fluorescein leakage and the extent of neovascularization as was observed in the flat mounts of choroidal tissue derived from the rats with induced CNV. The VEGF and IGF-1 mRNA levels were reduced following treatment with octreotide. Conclusion: The retrobulbar administration of octreotide may be an effective new therapeutic strategy for CNV. Copyright (c) 2009 S. Karger AG, Basel